PGS9 A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC INJECTABLE TREATMENT VERSUS SURGERY IN PATIENTS WITH SEVERE GASTRO ESOPHAGEAL REFLUX DISEASE IN FRANCE
Nov 1, 2003, 00:00 AM
10.1016/S1098-3015(10)61754-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)61754-8/fulltext
Section Title :
Section Order :
201
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)61754-8&doi=10.1016/S1098-3015(10)61754-8